Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis

New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits....

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Renliang, Chen, Baoxin, Duan, Peng, Zheng, Chanjiao, Shen, Huanyu, Liu, Qun, Yuan, Chen, Ou, Weilin, Zhou, Zhiheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5183769/
https://www.ncbi.nlm.nih.gov/pubmed/28058266
http://dx.doi.org/10.1155/2016/4543861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5183769/
https://www.ncbi.nlm.nih.gov/pubmed/28058266
http://dx.doi.org/10.1155/2016/4543861

Ejemplares similares